Antibiotic-impregnated central venous catheters do not change antibiotic resistance patterns by Turnbull, Isaiah R et al.




Antibiotic-impregnated central venous catheters do
not change antibiotic resistance patterns
Isaiah R. Turnbull
Washington University School of Medicine in St. Louis
Sara A. Buckman
Washington University School of Medicine in St. Louis
Christopher B. Horn
Washington University School of Medicine in St. Louis
Grant V. Bochicchio
Washington University School of Medicine in St. Louis
John E. Mazuski
Washington University School of Medicine in St. Louis
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Turnbull, Isaiah R.; Buckman, Sara A.; Horn, Christopher B.; Bochicchio, Grant V.; and Mazuski, John E., ,"Antibiotic-impregnated
central venous catheters do not change antibiotic resistance patterns." Surgical Infections.19,1. 40-47. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/6506
Antibiotic-Impregnated Central Venous Catheters
Do Not Change Antibiotic Resistance Patterns
Isaiah R. Turnbull, Sara A. Buckman, Christopher B. Horn, Grant V. Bochicchio, and John E. Mazuski
Abstract
Background: Antibiotic-impregnated central venous catheters (CVCs) decrease the incidence of infection in
high-risk patients. However, use of these catheters carries the hypothetical risk of inducing antibiotic resistance.
We hypothesized that routine use of minocycline and rifampin-impregnated catheters (MR-CVC) in a single
intensive care unit (ICU) would change the resistance profile for Staphylococcus aureus.
Methods: We reviewed antibiotic susceptibilities of S. aureus isolates obtained from blood cultures in a large
urban teaching hospital from 2002–2015. Resistance patterns were compared before and after implementation
of MR-CVC use in the surgical ICU (SICU) in August 2006. We also compared resistance patterns of S. aureus
obtained in other ICUs and in non-ICU patients, in whom MR-CVCs were not used.
Results: Data for rifampin, oxacillin, and clindamycin were available for 9,703 cultures; tetracycline resistance
data were available for 4,627 cultures. After implementation of MR-CVC use in the SICU, rifampin resistance
remained unchanged, with rates the same as in other ICU and non-ICU populations (3%). After six years of use
of MR-CVCs in the SICU, the rate of tetracycline resistance was unchanged in all facilities (1%–3%). The use
of MR-CVCs was not associated with any change in S. aureus oxacillin-resistance rates in the SICU (66% vs.
60%). However, there was a significant decrease in S. aureus clindamycin resistance (59% vs. 34%; p< 0.05) in
SICU patients.
Conclusions: Routine use of rifampin-minocycline-impregnated CVCs in the SICU was not associated with
increased resistance of S. aureus isolates to rifampin or tetracyclines.
Keywords: antibiotic resistance; central venous catheters
Although the National Health Care Safety Network(NHSN) has declared central line-associated blood
stream infection (CLABSI) should be a ‘‘never’’ event, there
were more than 16,000 cases reported to the NHSN in 2016.
These infections are associated with worse patient outcomes.
A recent meta-analysis found that CLABSI resulted in a 2.75-
fold increase in the risk of death [1]. Further, CLABSI during
an index hospitalization was associated with a significantly
higher hospital readmission rate and an increased length of
stay. Estimates of the cost of CLABSI range from $12,000 to
$56,000 per infection [2–4].
A wide range of interventions have been developed to
decrease CLABSI. Previous studies have demonstrated that
use of a bundle including full barrier precautions, appropriate
skin preparation, appropriate hand hygiene, and specific an-
atomic sites for placement can decrease CLABSI rates [5].
Further, administrative interventions, including multidisci-
plinary educational efforts and checklists, also can signifi-
cantly decrease the incidence of CLABSI [6]. However,
despite wide-ranging implementation of these measures,
CLABSI rates remain relatively high.
Over the last 17 years, the surgical intensive care unit (SICU)
at Barnes-Jewish Hospital has pursued efforts to decrease
CLABSI. This hospital houses a diverse cohort of patients,
including acute-care surgery and trauma patients, elective
general surgical patients, patients from other surgical special-
ties, and overflow medicine patients. In 1999, an education
program and follow-up behavioral intervention was instituted
to increase compliance with known best practices, as defined by
the U.S. Centers for Disease Control and Prevention (CDC)
CLABSI prevention bundle [6]; these measures indeed led to a
significant decrease in catheter-associated infections.
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Antimicrobial-impregnated catheters are another tool that
might reduce CLABSI. In 2002, routine use of central venous
catheters (CVCs) impregnated with chlorhexidine and silver-
sulfadiazine was initiated in the SICU and resulted in a small
yet significant improvement in CLABSI rates [7]. Subsequent
studies from other centers suggested that minocycline- and
rifampin-impregnated catheters (MR-CVC) were superior to
chlorhexidine/silver-sulfadiazine–impregnated catheters for
preventing CLABSI [8]. A prospective study in our SICU
documented that use of the MR-CVC was associated with a
significant reduction in CLABSI [9]. Therefore, since 2006,
only MR-CVC have been utilized for new central line inser-
tions in the SICU. A recent large meta-analysis supports these
findings, reporting that MR-CVC are associated with a sig-
nificantly lower risk of blood stream infections compared with
standard catheters, with an aggregate relative risk of 0.28 [8].
Given the high degree of scrutiny placed on CLABSI and the
demonstrated benefit of antibiotic-impregnated CVCs, these
catheters have become the standard of care in immunocom-
promised patient populations and in patients at high risk of line
infections such as burn patients and those requiring prolonged
central venous access.
Nonetheless, routine use of these catheters in all patients
may result in increased exposure of microorganisms to these
antibiotics, with the potential of developing significant re-
sistance to rifampin or tetracyclines [10,11]. Thus far, studies
investigating whether increased antibiotic resistance occurs
with use of MR-CVC [12] have given heterogeneous results,
although resistance to minocycline and rifampin has been
demonstrated in vitro [10,11]. Because mandatory utilization
of MR-CVC in the SICU at our institution began in Sep-
tember 2006 but not in other intensive care units (ICUs) or
among non-ICU patients, it was possible to track changes in
resistance within a single unit where exposure to the antibi-
otic impregnated-CVCs was high and compare it with other
areas of the hospital where exposure was essentially non-
existent. To measure the effect of MR-CVC on microbial
resistance patterns, we specifically monitored Staphylo-
coccus aureus susceptibilities; this micro-organism generally
is susceptible to rifampin and tetracyclines, but this suscep-
tibility could be altered by the selective pressure exerted by
MR-CVCs.
Patients and Methods
The study protocol was approved by the Washington
University Institutional Review Board. All blood cultures
positive for S. aureus from January 2002 through October
2015 within a comprehensive, de-identified hospital database
were selected for further evaluation. The hospital location
where the blood culture was obtained was recorded, the time
period in which the culture was obtained, and the antibiotic
susceptibilities of the isolates were entered in a database.
Data on susceptibilities to oxacillin, clindamycin, and ri-
fampin were available throughout the study period, but data
on doxycycline and tetracycline susceptibilities were avail-
able only from 2009–2015. Organisms resistant to either
doxycycline or tetracycline were considered tetracycline re-
sistant for analysis. Isolates reported as having intermediate
susceptibility were coded as resistant. There were no patient
identifiers available in the comprehensive database, and it
was not possible to determine how many blood cultures
positive for S. aureus from the same patient were included in
the database. There were no changes in how blood culture
results were documented in the comprehensive database
throughout the study period. Catheter-associated blood
stream infections were defined according to CDC-guidelines.
Positive cultures were grouped according to the year ob-
tained and whether they were obtained before or after Sep-
tember 2006, the point when insertion of MR-CVCs became
the standard practice in the SICU. However, SICU patients
could still have other central access lines, such as hemodi-
alysis or peripherally inserted central lines or catheters in-
serted at other locations, which were not MR-CVCs. In a
prior study, the prevalence of MR-CVCs among all central
lines in SICU patients during a portion of the study period
was 44% [9].
For analysis, rifampin resistance was compared before and
after August 2006. Rifampin resistance during these same
time periods was characterized in other ICU patients, in-
cluding those in the cardiothoracic surgical ICU, the medical
ICU, the neurological ICU, and the cardiac ICU and also in
non-ICU patients. Because the susceptibilities of S. aureus to
tetracyclines began to be reported only in 2009, yearly trends
in tetracycline resistance in the SICU and other locations
were compared, but a direct comparison before and after
institution of the use of MR-CVCs was not possible.
Chi-square tests were used to determine associations be-
tween aggregate resistance rates before and after implementa-
tion of MR-CVC use. Two-way analysis of variance followed
by the Tukey multiple comparisons test was used to assess for
differences in average annual resistance rates. A p value <0.05
was considered statistically significant. Statistical analyseswere
performed using SPSS version 23.0 (IBMCorp., Armonk, NY).
Results
We identified 10,483 blood cultures that were positive for
S. aureus during the period queried. Susceptibility data for
rifampin, oxacillin, and clindamycin were available for 9,703
of these cultures. For tetracyclines, data were available for
4,627 isolates obtained between 2009 and 2015, when testing
for tetracycline susceptibility was reported. The numbers of
cultures identified in the SICU, other-ICU, and non-ICU
populations, as well as the distribution before and after im-
plementation of routine insertion ofMR-CVCs in the SICU in
September 2006, are shown in Figure 1.
Rifampin susceptibilities were available for all S. aureus
isolates obtained during the study period (Table 1; Fig. 1). In
the period before MR-CVC use in the SICU, from January
2002–September 2006, 3% of S. aureus isolates in the SICU
(4/116) were resistant to rifampin; in the aggregate period
after implementation of universal MR-CVC use from Octo-
ber 2006 to October 2015, 3% (6/227) were resistant. This
difference was not significant by w2 analysis (Table 1,
Fig. 2A). The annual rate of rifampin resistance among
S. aureus isolates between 2002 and 2015 fluctuated within
the SICU, but no trend in the yearly percentage of rifampin
resistance or in the average annual rate of resistance in the
SICU was identified (Fig. 2A, B). In other ICU populations,
in which MR-CVC were not routinely utilized, the rate of
rifampin resistance before and after September 2006 was not
appreciably different from that measured in the SICU and did
not change significantly between the two time periods















































(Table 1; Fig. 2A). As in the SICU, annual rates of rifampin
resistance fluctuated somewhat, but there was no overall
trend observed between 2002 and 2015 (Fig. 2B). Although
resistance rates of S. aureus isolates obtained from patients in
non-ICU settings appeared to be slightly lower than those
obtained in either SICU or other ICU patients, this difference
was not statistically significant. There also was no trend to-
ward increased or decreased resistance throughout the study
period. Overall, there were no statistically significant dif-
ferences in rifampin resistance between the SICU, other ICU,
and non-ICU populations, either before or after im-
plementation of mandatory MR-CVC use in the SICU.
Data for tetracycline resistance, obtained from 2009–2015
(after implementation of routine use of MR-CVCs in the
SICU in 2006) was compared in the SICU, other ICU, and
non-ICU populations. Overall rates were low: 3% of isolates
(5/137) from SICU patients, 1% of isolates from other ICU
patients (5/446), and 3% of isolates from non-ICU patients
FIG. 1. Bacteremias with microbial cultures positive for Staphylococcus aureus from January 2002–October 2015. Of
these, 9,703/10,483 had complete data for oxacillin, rifampin, and clindamycin susceptibility; and 4,627 had data available
for tetracyclines. After September 1, 2006, all central venous catheters used in the surgical intensive care unit were
minocycline and rifampin impregnated.
Table 1. Antibiotic Resistance before and after Implementation of Standard Insertion
of MR-CVC in the SICU
SICU Other ICU Non-ICU
2002–2006 2006–2015 2002–2006 2006–2015 2002–2006 2006–2015
(n = 116) (n = 227) (n= 286) (n = 642) (n = 2,416) (n = 6,016)
Rifampin-resistant (%) 4 ( 3) 6 ( 3) 5 ( 2) 17 ( 3) 43 ( 2) 125 ( 2)
Oxacillin-resistant (%) 77 (66) 137 (60) 164 (57) 393 (57) 1,360 (56) 3,344 (55)
Clindamycin-resistant (%) 69 (59)a 78 (34)a 128 (44) 299 (47)a 1,097 (45)a 2,492 (41)a
aP< 0.05 by w2 test.
MR-CVC =methicillin/rifampin-impregnated central venous catheter; SICU = surgical ICU; ICU = intensive care unit.















































(133/4,004) (Table 2). Annual rates of tetracycline resistance
fluctuated within each population, but no trends in resistance
were noted among any of the populations (Fig. 3B), and the
average annual rates were not significantly different (Fig. 3A).
Changes in the sensitivity to oxacillin and clindamycin
also were assessed, as these could reflect the relative preva-
lence of methicillin-resistant S. aureus (MRSA) strains in
isolates obtained before and after implementation of use of
MR-CVCs. Oxacillin-resistant strains were assumed to be
MRSA. Among all patients, 56.8% of S. aureus isolates were
MRSA strains in the period before September 2006 and
56.2% of isolates were MRSA strains after September 2006.
There were no significant changes in the incidence of MRSA
in the SICU, other ICU, or the non-ICU populations with
initiation of routine use of MR-CVC in the SICU (Table 1;
Fig. 4A). Evaluation of annual rates of oxacillin resistance
demonstrated no temporal change throughout the study pe-
riod (Fig. 4B).
In the period prior to use of the MR-CVC, the aggregate
clindamycin resistance rate in S. aureus isolates from SICU
patients was higher than the rate observed in isolates from
other ICU patients and from the non-ICU population, al-
though this was statistically significant only for the com-
parison with the latter (Table 1; Fig. 5A). In the period after
implementation of universal insertion of MR-CVCs, however,
there was a significant decrease in clindamycin resistance ob-
served in the SICU isolates compared with the pre-
implementation period (59% vs. 34%; Table 1; Fig. 5A). Rates
of clindamycin resistance in isolates from SICU patients were
actually lower than those observed in the non-SICUpopulations,
FIG. 2. Rifampin resistance rates in Staphylococcus aureus
isolates. (A) Average annual resistance rate before and after
initiation of minocycline- and rifampin-impregnated catheter
use in the surgical intensive care unit. (B) Annual rifampin
resistance rates between 2002 and 2015 in the surgical inten-
sive care unit (ICU), non-ICU, and other ICU populations.
Vertical bar indicates the initiation of mandatory minocycline-
and rifampin-impregnated catheter use in the SICU.
Table 2. Tetracycline Class Resistance after
Nine Years of Protocol MR-CVC in SICU
Tetracycline- Resistant /Total (%)
SICU 5/137 (3)
Other ICU 5/446 (1)
Non-ICU 133/4044 (3)
MR-CVC=methicillin/rifampin-impregnated central venous cathe-
ter; SICU= surgical ICU; ICU= intensive care unit.
FIG. 3. Tetracycline resistance rates in Staphylococcus
aureus isolates. Doxycycline and tetracycline resistance data
were pooled for the period from 2009–2015. (A) Average
annual tetracycline resistance rate in the surgical intensive
care unit (ICU), non-ICU, and other ICU populations. (B)
Annual tetracycline resistance rate in the surgical ICU, non-
ICU, and other-ICU populations.















































but this difference was statistically significant only for isolates
from patients in other ICUs (Table 1; Fig. 5A). There appeared
to be a trend toward decreased clindamycin resistance on an
annual basis after routine use began of MR-CVCs in the SICU
population (Fig. 5B), although this trend did not reach statistical
significance. There was no change in clindamycin resistance
observed in S. aureus isolates from patients in other ICUs before
or after September 2006, but there was a parallel, although less
dramatic, decrease in clindamycin resistance in isolates from
non-ICU patients before and after September 2006, which did
reach statistical significance (45% vs. 41%; see Table 1).
To determine if our change to antibiotic-impregnated
catheters was temporally associated with a change in CVC
usage in the SICU, we measured the total number of catheter
days from 2002–2015 in both the SICU and other-ICU pop-
ulations. To determine if there were changes in catheter ex-
posure over time, simple linear regression was calculated to
predict the number of catheter days over time. A significant
regression equation was found (F = 13.0; p < 0.05; R2 = 052)
demonstrating that there was a statistically significant increase
in CVC use in the SICU over time. There was no significant
trend in the other ICU populations (F= 1.8; p= 0.2; R2= 0.13).
These data demonstrate that since the institution protocol MR-
CVL use in the SICU, total line exposure in the SICU has
increased, whereas there has been no change in line exposure
in the other ICU populations.
We also measured the rate of CLABSI at our institution.
We previously reported that MR-CVL led to a significant
reduction in the CLABSI rate in our SICU [9]. We find that
we have had a continued low rate of CLABSI in both our
SICU and other ICU populations, with average annual rates
FIG. 4. Oxacillin resistance rates in Staphylococcus aureus
isolates. (A) Average annual oxacillin resistance rate before
and after initiation of minocycline- and rifampin-impregnated
catheter use in the surgical intensive care unit (ICU). (B)
Annual oxacillin resistance rates between 2002 and 2015 in
the surgical intensive care unit ((ICU), non-ICU, and other
ICU populations. Vertical bar indicates initiation of manda-
tory drug-impregnated catheter use in the surgical ICU.
FIG. 5. Clindamycin resistance rates in Staphylococcus
aureus isolates. (A) Average annual clindamycin resistance
rate before and after initiation of minocycline- and rifampin-
impregnated catheter use in the surgical intensive care unit
(ICU). aP< 0.05 by analysis of variance followed by Tukey
multiple comparisons test. (B) Annual clindamycin resistance
rates between 2002 and 2015 in the surgical ICU, non-ICU,
and other ICU populations. Vertical bar indicates initiation of
mandatory drug-impregnated catheter use in the surgical ICU.















































of <2 CLABSI/1,000 line-days (Fig. 6B). Importantly, fewer
than 5% of the CLABSI in our institution are caused by
S. aureus, and therefore, the bacteremia results we report
above are rarely CLABSI but in contrast represent non-
catheter-associated primary or secondary bacteremias.
Discussion
This retrospective study evaluated the antibiotic suscepti-
bilities of all S. aureus isolates from blood cultures for four
years before and nine years after initiation of mandatory use
of a MR-CVC in the SICU at this institution. Use of these
catheters was not associated with any notable increase in
resistance to rifampin or tetracyclines. Further, resistance
patterns in other ICUs and throughout the institution did not
diverge significantly from those seen in the SICU, providing
an internal control to verify these findings. To our knowledge,
this is the longest follow-up reported to date of antibiotic
resistance after initiation of MR-CVC use.
These results significantly expand on the study by Ramos
et al., who also measured antibiotic sensitivities before and
after introduction of MR-CVC. These authors compared the
average rate of resistance in 1998, one year prior to the in-
troduction of MR-CVC, with the average rate of resistance in
2006, seven years after the introduction. During this interval,
there was intermittent use of MR-CVC until 2003, after
which MR-CVC use became mandatory. Similar to our re-
sults, that study reported no increase in resistance among
bacterial isolates after introduction of the MR-CVC.
Although implementation of MR-CVC was not associated
with a change in susceptibility to tetracyclines or rifampin, an
unexpected finding was the significant change in the sus-
ceptibility profile of S. aureus to clindamycin in isolates
obtained from patients in the SICU after initiation of MR-
CVC use. There was an almost 50% decrease in clindamycin
resistance between 2006 and 2015. Prior to that time, clin-
damycin resistance rates in the SICU were significantly
higher than the rates in non-ICU populations, but after the
introduction of MR-CVC, clindamycin resistance rates re-
gressed toward themean hospital rate and then became lower.
There was no significant change in clindamycin resistance in
the other ICU populations and only a small decrease in the
non-ICU populations, suggesting that the change occurred
primarily in SICU patients.
One potential explanation for this phenomenon was that use
of MR-CVCs led to selection of different S. aureus strains
causing bacteremia in SICU patients or, alternatively, to an
overall change in the types of S. aureus strains colonizing SICU
patients. However, this change in susceptibility of S. aureus to
clindamycin over time may well have been an independent
phenomenon related to a shift in the incidence of S. aureus
infections from the hospital-acquired USA100 MRSA strain to
the community-associated USA300 MRSA strain. The
USA300 strain emerged as an important pathogen during the
time of this study [13]. Further, this institution is in a geographic
area where there is a high degree of USA300 emergence [13].
Of note, the USA300 strain is characterized by less antibiotic
resistance than the USA100 strain [14–16]. The USA300 strain
generally is susceptible to clindamycin (6% resistance),
whereas the USA100 strain is not (95% resistance) [17]. A
remaining question, however, is why the change in S. aureus
susceptibility to clindamycin was observed only in SICU pa-
tients and not in other ICU patients and only minimally in the
general hospital population. It is possible that SICU patients
have a much greater risk of infection with the USA300 MRSA
strain because of its propensity to produce skin and soft tissue
infections [14], creating a lower risk for patients in other ICUs.
Nonetheless, this difference makes it difficult to conclude that
an overall change in microbial ecology in the geographic area
was solely responsible for this change in S. aureus susceptibility
that was limited primarily to SICU patients.
Our study design has several strengths that support our
conclusions. First, MR-CVCs have been inserted in the SICU
for more than nine years, potentially allowing any accumu-
lated changes in antimicrobial resistance over this long period
of time to be detected. Second, because MR-CVCs have not
been used routinely in other ICUs in this institution, changes in
antibiotic resistance independent of MR-CVC use could have
been observed. Finally, the extensive database available al-
lowed analysis of more than 9,500 culture results, permitting
detection of relatively minor changes in antibiotic resistance.
FIG. 6. Central venous catheter line-days and central line-
associated blood stream infections (CLABSI) in surgical
(ICU) and other ICU populations. (A) Average number of
line-days per month was calculated for the surgical ICU and
other ICU populations. A simple linear regression was cal-
culated to determine changes in line use over time. Surgical
ICU: Y = 12.72X-25030; R2 = 0.52; F = 13; p< 0.01. Other
ICU: Y = 14.2X-26839; R2 = 0.13; F = 1.8; p= 0.2. (B) The
CLABSI rate/1,000 line-days was calculated. CLABSI was
defined on basis of U.S. Centers for Disease Control and
Prevention guidelines.















































Despite these strengths, there are several limitations to this
study. First, it was retrospective, thus providing only asso-
ciative data and not allowing conclusions to be drawn re-
garding causality or mechanism. Moreover, the data are
indirect, utilizing a database of culture results to link isolation
of a microorganism with a specific resistance profile to the
times and locations where use of MR-CVCs differed. Direct
patient-linked data were not available using this study design;
we are unable to correlate our resistant cultures with specific
use of MR-CVCs. This will be an important issue for future
studies. We did assess the number of CVC-days in the SICU
vs. other ICU populations and found that the number of CVC
days increased over the study period in the SICU but not in
other ICU populations, demonstrating an increasing exposure
of the SICU microbiome MR-CVL in the SICU over the
study period. Another potential limitation is the reliance on S.
aureus bacteremia data. All of these cultures are blood cul-
tures, but we cannot determine if these are CLABSI and have
no specific data regarding the relation between catheter use
and bacteremia for specific patients. At our institution,
S. aureus accounts for less than 5% of CLABSI; therefore, the
majority of these positive cultures are bacteremia but possi-
bly not CLABSI. As an additional limitation, we report only
data for S. aureus, and resistance in other organisms isolated
from different sites certainly could have been impacted by
use of the MR-CVC. Prior in vitro studies have demonstrated
inducible resistance to rifampin and tetracycline in both
Pseudomonas aeruginosa and S. epidermidis. With regard to
S. aureus susceptibilities, only qualitative data were avail-
able. Data regarding minimal inhibitory concentrations or
zone of inhibitions might have made it possible to monitor
more subtle quantitative changes in antimicrobial suscepti-
bility. In addition, we report only data on S. aureus bacter-
emia. The study design does not allow us to assess changes in
other microbial cultures, and an analysis of the resistance
profile of a broader cohort of microbes, including surveil-
lance cultures, will be an important next step. However, the
absence of these data does not temper the strength of our
conclusions that use ofM-R catheters was not associated with
anymeaningful changes in resistance of blood stream isolates
of S. aureus to rifampin and tetracyclines.
In addition, we cannot account specifically for other
changes in practice that could alter the local microbial re-
sistance pattern. Within the SICU, we have followed CDC
best practice guidelines for CVC insertion since 2002, and no
systematic changes were made to our line insertion protocol
over the study period. Since 2002, there have been no specific
institutional changes designed to alter resistance to rifampin
or tetracyclines. We cannot exclude the possibility that in-
terventions in infection-control practices over the study pe-
riod contributed to changes in local antibiotic resistance
profile, although it seems unlikely that such non-specific ef-
forts would have altered resistance specifically to rifampin
and tetracyclines. Moreover, a review of institutional hospital
infection-control protocols does not demonstrate any signif-
icant, systematic institutional changes over this time period.
Finally, changes in prescribing of relevant systemic antimi-
crobials were not evaluated. Use of systemic antibiotics
might influence emerging resistance to a far greater degree
than use of the MR-CVC, making any altered susceptibility
difficult to detect. However, the relatively static resistance
profiles (except to clindamycin) observed across all units
suggest that this confounder did not have a major influence on
these results.
This study does lay the groundwork for future investiga-
tions into any role that MR-CVCs play in altering microbial
ecology. Such work would preferentially utilize patient-
specific data to determine if the presence and duration ofMR-
CVCs had any association with increased resistance among
microbial isolates. Such a study could overcome some of the
limitations of this present study. However, it may not provide
conclusive data, given the low overall incidence of bacter-
emia caused by any particular pathogen in ICU patients, and
would be much more labor intensive.
In conclusion, despite nine years of continuous use of MR-
CVCs in the SICU, generalized emergence of antimicrobial
resistance of S. aureus to rifampin and tetracyclines was not
observed. Of interest, use of MR-CVCs was temporally as-
sociated with a decrease in resistance of S. aureus to clin-
damycin, although it is unclear if this reflected overall changes
inMRSA ecology or an effect of these catheters. These data do
not support the hypothesis that use of MR-CVCs leads to a
significant increase in antibiotic resistance. Given the benefit
of these catheters in reducing CLABSI, their use in selected
patients remains an appropriate option for decreasing overall
rates of CLABSI.
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